Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells

In this study, we have explored the possibility of the combination of the high reactivity of nano Fe3O4 or Au nanoparticles and daunomycin, one of the most important antitumor drugs in the treatment of acute leukemia clinically, to inhibit MDR of K562/A02 cells. Initially, to determine whether the magnetic nanoparticle Fe3O4 and Au can facilitate the anticancer drug to reverse the resistance of cancer cells, we have explored the cytotoxic effect of daunomycin (DNR) with and without the magnetic nano-Fe3O4 or nano-Au on K562 and K562/A02 cells by MTT assay. Besides, the intracellular DNR concentration and apoptosis of the K562/A02 cells was further investigated by flow cytometry and confocal fluorescence microscopic studies. The MDR1 gene expression of the K562/A02 cells was also studied by RT-PCR method. Our results indicate that 5.0 × 10−7 M nano-Fe3O4 or 2.0 × 10−8 M nano-Au is biocompatible and can apparently raise the intracellular DNR accumulation of the K562/A02 cells and increase the apoptosis of tumor cells. Moreover, our observations illustrate that although these two kinds of nanoparticles themselves could not lower the MDR1 gene expression of the K562/A02 cells, yet they could degrade the MDR1 gene level when combining with anticancer drug DNR. This raises the possibility to combine the nano-Fe3O4 or nano-Au with DNR to reverse the drug resistance of K562/A02 cells, which could offer a new strategy for the promising efficient chemotherapy of the leukemia patients.

[1]  Y. Hashimoto,et al.  Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. , 1997, British Journal of Cancer.

[2]  F. Gao,et al.  Novel nanocomposite of nano fe(3)o(4) and polylactide nanofibers for application in drug uptake and induction of cell death of leukemia cancer cells. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[3]  T. Litman,et al.  Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. , 1997, Biochimica et biophysica acta.

[4]  Dan Du,et al.  Electrochemical immunoassay of membrane P-glycoprotein by immobilization of cells on gold nanoparticles modified on a methoxysilyl-terminated butyrylchitosan matrix. , 2005, Biochemistry.

[5]  Chenjie Xu,et al.  Linking Hydrophilic Macromolecules to Monodisperse Magnetite (Fe(3)O(4)) Nanoparticles via Trichloro-s-triazine. , 2006, Chemistry of materials : a publication of the American Chemical Society.

[6]  P Couvreur,et al.  Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. , 2000, Biomaterials.

[7]  P. Twentyman Cyclosporins as drug resistance modifiers. , 1992, Biochemical pharmacology.

[8]  Tim Liedl,et al.  Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. , 2005, Nano letters.

[9]  J. Benoit,et al.  Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[10]  F. Baas,et al.  Mechanisms of multidrug-resistance , 1994 .

[11]  T. Tsuruo,et al.  Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. , 1988, Cancer research.

[12]  John A. Kellen,et al.  Mechanisms of Multidrug Resistance , 1995 .

[13]  D. Leslie-Pelecky,et al.  Iron oxide nanoparticles for sustained delivery of anticancer agents. , 2005, Molecular pharmaceutics.

[14]  R. Advani,et al.  Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). , 1999, Blood.

[15]  P. Couvreur,et al.  Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. , 1992, Biochemical pharmacology.

[16]  F. Gao,et al.  Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. , 2006, Leukemia research.

[17]  J C Sanford,et al.  Optimizing the biolistic process for different biological applications. , 1993, Methods in enzymology.

[18]  X. Shen,et al.  Preparation of magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor. , 2004, World journal of gastroenterology.

[19]  B. Chu,et al.  Preparation and Properties of Magnetite and Polymer Magnetite Nanoparticles , 1999 .

[20]  F. Gao,et al.  Synergistic enhancement effect of magnetic nanoparticles on anticancer drug accumulation in cancer cells , 2006, Nanotechnology.

[21]  Dong-Hwang Chen,et al.  Preparation and characterization of YADH-bound magnetic nanoparticles , 2002 .

[22]  L. Ratner,et al.  Multidrug resistance transporters and modulation , 2000, Current opinion in oncology.

[23]  P Couvreur,et al.  Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Jianxiang Wang,et al.  Expression of sorcin predicts poor outcome in acute myeloid leukemia. , 2003, Leukemia research.

[25]  Robert Langer,et al.  Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. , 2005, Analytical chemistry.

[26]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[27]  S. Hegewisch‐Becker MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. , 1996, Leukemia.

[28]  P. Couvreur,et al.  Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. , 1994, European journal of cancer.